Publications by authors named "Keith M Olson"

Claim this Profile
N
Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy.
Keith M Olson, Andrea L Devereaux, Payal Chatterjee, Savanah L Saldaña-Shumaker, Amanda Shafer

Front Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice.
Keith M Olson, Todd M Hillhouse, Gwendolyn E Burgess, Joshua L West, James E Hallahan

J Pharmacol Exp Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose.
Alex Disney, Keith M Olson, Amanda M Shafer, Sierra C Moore, Jessica P Anand

ACS Chem Neurosci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.
Lisa R Gerak, David R Maguire, Gerta Cami-Kobeci, Keith M Olson, John R Traynor

Behav Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands.
Keith M Olson, Andra Campbell, Andrew Alt, John R Traynor

ACS Pharmacol Transl Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs.
Wallace K B Chan, Keith M Olson, Jesse W Wotring, Jonathan Z Sexton, Heather A Carlson

Sci Rep· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric Modulator Leads Hiding in Plain Site: Developing Peptide and Peptidomimetics as GPCR Allosteric Modulators.
Keith M Olson, John R Traynor, Andrew Alt

Front Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice.
Todd M Hillhouse, Keith M Olson, James E Hallahan, Lauren G Rysztak, Bryan F Sears

J Pharmacol Exp Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids.
Keith M Olson, David I Duron, Daniel Womer, Ryan Fell, John M Streicher

PLoS One· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice.
Keith M Olson, Attila Keresztes, Jenna K Tashiro, Lisa V Daconta, Victor J Hruby

J Med Chem· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.
Keith M Olson, Wei Lei, Attila Keresztes, Justin LaVigne, John M Streicher

Yale J Biol Med· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Aswini Kumar Giri, Christopher R Apostol, Yue Wang, Brittany L Forte, Tally M Largent-Milnes, Keith M Olson

J Med Chem· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis